pcDNA3.1-TK1 Citations (5)

Originally described in: Pyrimidine metabolic rate limiting enzymes in poorly-differentiated hepatocellular carcinoma are signature genes of cancer stemness and associated with poor prognosis.
Yeh HW, Lee SS, Chang CY, Hu CM, Jou YS Oncotarget. 2017 Sep 8;8(44):77734-77751. doi: 10.18632/oncotarget.20774. eCollection 2017 Sep 29. PubMed Journal

---

Articles Citing pcDNA3.1-TK1

Articles
Optimization of a Novel 2 + 2 BCMA x CD3 Bispecific Antibody for Minimized Cytokine Release and Potent Efficacy. Wu D, Huang L, Naren G, Zhang R, Gong S, Wu X, Wu C. Mol Cancer Ther. 2025 Oct 1;24(10):1600-1610. doi: 10.1158/1535-7163.MCT-24-0846. PubMed
CYB5R4 sustains endothelial proliferation and ischemia-induced angiogenesis by maintaining RRM2-dependent nucleotide balance. Yuan S, Hahn SA, Colussi NC, Mullett SJ, Gelhaus SL, Schopfer FJ, Straub AC. bioRxiv [Preprint]. 2025 Sep 20:2025.09.17.676962. doi: 10.1101/2025.09.17.676962. PubMed
SNAT1 (SLC38A1) Is Not the Main Glutamine Transporter in Melanoma, but Controls Metabolism via Glutamine-Dependent Activation of P62 (SQSTM1)/cMYC-Axis. Lorentz S, Bohme-Schafer I, Konig J, Sticht H, Bosserhoff AK. Cancers (Basel). 2026 Mar 25;18(7):1068. doi: 10.3390/cancers18071068. PubMed
Antibodies blocking PlGF or VEGF interactions with the NRP1 receptor mediate antiproliferative effects. Blackman SA, Qerqez AN, Lee AG, Johnson NV, Owens JM, Lai GS, Aldrich EC, Sprenger KG, Lee J, Verrier S, Stoddart MJ, Nguyen AW, Maynard JA. J Biol Chem. 2026 Jun;302(6):111476. doi: 10.1016/j.jbc.2026.111476. Epub 2026 Apr 17. PubMed
Molecular Mechanism of NSUN6-Mediated Epigenetic Modifications in the Malignant Progression of Colorectal Cancer Cells. Dong Z, Wang Y, Chen J, Yu W, Chen Y, Peng W, Cheng W. FASEB J. 2026 May 31;40(10):e71883. doi: 10.1096/fj.202600351R. PubMed

If you have published an article using this material, please email us at to have your article added to this page.